SRZN Surrozen, Inc./DE
Nasdaq · SEC CIK 1824893 · EDGAR
- Bought, last 12 months
- $16.85M 14 purchases by 6 insiders
- Sold, last 12 months
- $7.23M 6 sales by 4 insiders
- Filings on record
- 133 since 2021-08-13, latest 2026-07-24 21:00
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| TCG Crossover GP II, LLC | 10% | — | $6.91M |
| Kutzkey Tim | Dir, 10% | $5.98M | — |
| COLUMN GROUP III GP, LP | 10% | $4.99M | — |
| TCG Crossover Fund II, L.P. | 10% | $4.68M | — |
| Column Group Opportunity III GP, LP | 10% | $641.6K | — |
| TCG Opportunity III GP, LLC | 10% | $357.3K | — |
| TCG Crossover GP III, LLC | 10% | $202.5K | — |
| Parker Craig C | CEO, Dir | — | $150.8K |
| Williams Charles O | COO | — | $99.0K |
| Li Yang | Exec. VP, Research | — | $75.0K |
Transactions 75
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2026-07-24 21:00 | 2026-07-22 | SRZN | TCG Crossover GP II, LLC | 10% | S - Sale | $21.25 | -325.0K | 574.0K | -36% | -$6.91M |
| 2026-06-16 16:55 | 2026-06-15 | SRZN | Maleki Andrew Pedrum | CFO | A - Grant | $19.01 | +607 | 607 | New | +$11.5K | |
| 2026-06-16 16:51 | 2026-06-15 | SRZN | Li Yang | Exec. VP, Research | A - Grant | $8.11 | +1,666 | 18.9K | +10% | +$13.5K | |
| 2026-06-16 16:47 | 2026-06-15 | SRZN | Williams Charles O | COO | A - Grant | $8.11 | +1,666 | 18.2K | +10% | +$13.5K | |
| 2026-06-16 16:44 | 2026-06-15 | SRZN | Parker Craig C | CEO, Dir | A - Grant | $8.11 | +1,622 | 18.2K | +10% | +$13.2K | |
| D | 2026-05-05 16:58 | 2026-05-01 | SRZN | Li Yang | Exec. VP, Research | M - OptEx | — | +4,375 | 18.8K | +30% | — |
| D | 2026-05-05 16:58 | 2026-05-04 | SRZN | Li Yang | Exec. VP, Research | S - Sale+OE | $33.33 | -1,584 | 17.2K | -8% | -$52.8K |
| D | 2026-05-05 16:54 | 2026-05-01 | SRZN | Williams Charles O | COO | M - OptEx | — | +5,625 | 18.6K | +43% | — |
| D | 2026-05-05 16:54 | 2026-05-04 | SRZN | Williams Charles O | COO | S - Sale+OE | $33.33 | -2,036 | 16.6K | -11% | -$67.9K |
| D | 2026-05-05 16:51 | 2026-05-01 | SRZN | Parker Craig C | CEO, Dir | M - OptEx | — | +12.5K | 21.1K | +146% | — |
| D | 2026-05-05 16:51 | 2026-05-04 | SRZN | Parker Craig C | CEO, Dir | S - Sale+OE | $33.33 | -4,524 | 16.6K | -21% | -$150.8K |
| 2026-04-01 17:43 | 2026-03-31 | SRZN | Li Yang | Exec. VP, Research | G - Gift | $0.00 | -1,666 | 14.4K | -10% | $0 | |
| MI | 2026-03-25 | 2026-03-23+ | SRZN | TCG Crossover Fund II, L.P. | 10% | P - Purchase | $24.72 | +121.9K | 683.2K | +22% | +$3.01M |
| MI | 2026-03-16 | 2026-03-12+ | SRZN | TCG Crossover Fund II, L.P. | 10% | P - Purchase | $24.91 | +49.0K | 657.3K | +8% | +$1.22M |
| MI | 2026-02-13 | 2026-02-11+ | SRZN | TCG Crossover Fund II, L.P. | 10% | P - Purchase | $23.60 | +18.9K | 651.1K | +3% | +$444.9K |
| MI | 2026-02-03 | 2026-01-30+ | SRZN | TCG Crossover GP III, LLC | 10% | P - Purchase | $21.65 | +9,357 | 639.5K | +1% | +$202.5K |
| MI | 2026-01-20 | 2026-01-15+ | SRZN | Kutzkey Tim | Dir, 10% | P - Purchase | $19.74 | +32.5K | 891.8K | +4% | +$641.6K |
| MI | 2026-01-20 | 2026-01-15+ | SRZN | Column Group Opportunity III GP, LP | 10% | P - Purchase | $19.74 | +32.5K | 891.8K | +4% | +$641.6K |
| MI | 2026-01-15 | 2026-01-13+ | SRZN | Kutzkey Tim | Dir, 10% | P - Purchase | $19.86 | +18.0K | 996.5K | +2% | +$357.3K |
| MI | 2026-01-15 | 2026-01-13+ | SRZN | TCG Opportunity III GP, LLC | 10% | P - Purchase | $19.86 | +18.0K | 996.5K | +2% | +$357.3K |
| MI | 2026-01-08 | 2026-01-06 | SRZN | COLUMN GROUP III GP, LP | 10% | P - Purchase | $19.89 | +15.1K | 989.9K | +2% | +$300.3K |
| MI | 2026-01-08 | 2026-01-06 | SRZN | Kutzkey Tim | Dir, 10% | P - Purchase | $19.89 | +15.1K | 876.6K | +2% | +$300.3K |
| D | 2026-01-06 | 2026-01-05 | SRZN | Williams Charles O | COO | S - Sale+OE | $19.87 | -1,566 | 13.0K | -11% | -$31.1K |
| D | 2026-01-06 | 2026-01-02 | SRZN | Williams Charles O | COO | M - OptEx | — | +3,500 | 14.5K | +32% | — |
| D | 2026-01-06 | 2026-01-02 | SRZN | Li Yang | Exec. VP, Research | M - OptEx | — | +2,500 | 17.2K | +17% | — |
| D | 2026-01-06 | 2026-01-05 | SRZN | Li Yang | Exec. VP, Research | S - Sale+OE | $19.87 | -1,118 | 16.1K | -6% | -$22.2K |
| 2025-12-16 | 2025-12-15 | SRZN | Parker Craig C | CEO, Dir | A - Grant | $8.11 | +1,553 | 8,577 | +22% | +$12.6K | |
| 2025-12-16 | 2025-12-15 | SRZN | Williams Charles O | COO | A - Grant | $8.11 | +1,666 | 11.0K | +18% | +$13.5K | |
| 2025-12-16 | 2025-12-15 | SRZN | Li Yang | Exec. VP, Research | A - Grant | $8.11 | +1,666 | 14.7K | +13% | +$13.5K | |
| MI | 2025-12-08 | 2025-12-04+ | SRZN | COLUMN GROUP III GP, LP | 10% | P - Purchase | $19.22 | +36.1K | 981.9K | +4% | +$694.8K |
| MI | 2025-12-08 | 2025-12-04+ | SRZN | Kutzkey Tim | Dir, 10% | P - Purchase | $19.22 | +36.1K | 869.5K | +4% | +$694.8K |
| MI | 2025-12-02 | 2025-11-13 | SRZN | Kutzkey Tim | Dir, 10% | P - Purchase | $12.65 | +315.5K | 852.5K | +59% | +$3.99M |
| MI | 2025-11-17 | 2025-11-13 | SRZN | COLUMN GROUP III GP, LP | 10% | P - Purchase | $12.65 | +315.5K | 852.5K | +59% | +$3.99M |
| 2025-06-16 | 2025-06-13 | SRZN | Li Yang | Exec. VP, Research | A - Grant | $8.06 | +400 | 13.0K | +3% | +$3,224 | |
| 2025-06-16 | 2025-06-13 | SRZN | Williams Charles O | CFO, COO | A - Grant | $8.06 | +400 | 9,382 | +4% | +$3,224 | |
| 2025-06-16 | 2025-06-13 | SRZN | Parker Craig C | CEO, Dir | A - Grant | $8.06 | +400 | 7,024 | +6% | +$3,224 | |
| DMI | 2025-03-28 | 2025-03-26 | SRZN | Column Group Opportunity III, LP | 10% | P - Purchase | $11.60 | +1.03M | 704.3K | New | +$12.00M |
| 2025-01-06 | 2025-01-02 | SRZN | Williams Charles O | CFO, COO | M - OptEx | — | +3,500 | 10.2K | +53% | — | |
| 2025-01-06 | 2025-01-03 | SRZN | Williams Charles O | CFO, COO | S - Sale+OE | $17.37 | -1,181 | 8,982 | -12% | -$20.5K | |
| 2025-01-06 | 2025-01-03 | SRZN | Li Yang | Exec. VP, Research | S - Sale+OE | $17.37 | -843 | 13.3K | -6% | -$14.6K | |
| 2025-01-06 | 2025-01-02 | SRZN | Li Yang | Exec. VP, Research | M - OptEx | — | +2,500 | 14.2K | +21% | — | |
| 2024-06-18 | 2024-06-14 | SRZN | Parker Craig C | CEO, Dir | A - Grant | $5.67 | +400 | 5,824 | +7% | +$2,268 | |
| 2024-06-18 | 2024-06-14 | SRZN | Li Yang | Exec. VP, Research | A - Grant | $5.67 | +400 | 10.9K | +4% | +$2,268 | |
| 2024-06-18 | 2024-06-14 | SRZN | Williams Charles O | CFO, COO | A - Grant | $5.67 | +400 | 5,863 | +7% | +$2,268 | |
| MAI | 2024-04-17 | 2024-04-04 | SRZN | Kutzkey Tim | Dir, 10% | P - Purchase | $15.50 | +193.5K | 327.0K | +145% | +$3.00M |
| MAI | 2024-04-17 | 2024-04-04 | SRZN | COLUMN GROUP III-A, LP | 10% | P - Purchase | $15.50 | +193.5K | 327.0K | +145% | +$3.00M |
| D | 2024-04-08 | 2024-04-04 | SRZN | Parker Craig C | CEO, Dir | P - Purchase | — | +1,474 | 1,474 | New | — |
| DMI | 2024-04-08 | 2024-04-04 | SRZN | COLUMN GROUP III GP, LP | 10% | P - Purchase | $15.50 | +193.5K | 294.8K | +191% | +$3.00M |
| D | 2024-04-08 | 2024-04-04 | SRZN | Williams Charles O | CFO, COO | P - Purchase | — | +1,474 | 1,474 | New | — |
| DMI | 2024-04-08 | 2024-04-04 | SRZN | Kutzkey Tim | Dir, 10% | P - Purchase | $15.50 | +193.5K | 294.8K | +191% | +$3.00M |
| 2023-12-18 | 2023-12-15 | SRZN | Williams Charles O | CFO | A - Grant | $5.67 | +2,085 | 2,085 | New | +$11.8K | |
| 2023-12-18 | 2023-12-15 | SRZN | Parker Craig C | CEO, Dir | A - Grant | $5.67 | +2,046 | 2,046 | New | +$11.6K | |
| 2023-12-18 | 2023-12-15 | SRZN | Li Yang | Exec. VP, Research | A - Grant | $5.67 | +2,085 | 2,085 | New | +$11.8K | |
| 2023-06-20 | 2023-06-15 | SRZN | Williams Charles O | CFO | A - Grant | $0.38 | +25.0K | 34.6K | +261% | +$9,500 | |
| 2023-06-20 | 2023-06-15 | SRZN | Yeh Wen-Chen | CSO | A - Grant | $0.38 | +17.6K | 27.2K | +184% | +$6,702 | |
| 2023-06-20 | 2023-06-15 | SRZN | Parker Craig C | CEO, Dir | A - Grant | $0.38 | +25.0K | 34.6K | +261% | +$9,500 | |
| 2022-12-19 | 2022-12-15 | SRZN | Williams Charles O | CFO | A - Grant | $0.41 | +9,578 | 9,578 | New | +$3,927 | |
| 2022-12-19 | 2022-12-15 | SRZN | Yeh Wen-Chen | CSO | A - Grant | $0.41 | +9,578 | 229.1K | +4% | +$3,927 | |
| 2022-12-19 | 2022-12-15 | SRZN | Parker Craig C | CEO, Dir | A - Grant | $0.41 | +9,578 | 9,578 | New | +$3,927 | |
| 2022-12-19 | 2022-12-15 | SRZN | Vanhove Geertrui | Chief Medical Off | A - Grant | $0.41 | +9,578 | 32.4K | +42% | +$3,927 | |
| DMI | 2022-12-15 | 2022-12-14 | SRZN | Soffer Benny | 10% | S - Sale | — | -5.38M | 0 | -100% | — |
| DMI | 2021-08-13 | 2021-08-11 | SRZN | Consonance Capman GP, LLC | 10% | A - Grant | — | +3.50M | 500.0K | New | — |
| DMI | 2021-08-13 | 2021-08-11 | SRZN | Consonance Capman GP, LLC | 10% | D - Sale to Iss | — | -1.00M | 0 | -100% | — |
| D | 2021-08-13 | 2021-08-11 | SRZN | Haqq Christopher | Former Dir | A - Grant | — | +30.0K | 30.0K | New | — |
| DI | 2021-08-13 | 2021-08-11 | SRZN | Consonance Life Sciences | Former 10% Holder | J - Other | — | -759.0K | 1.45M | -34% | — |
| DMI | 2021-08-13 | 2021-08-11 | SRZN | Consonance Life Sciences | Former 10% Holder | D - Sale to Iss | — | -1.89M | 0 | -100% | — |
| DMI | 2021-08-13 | 2021-08-11 | SRZN | Consonance Life Sciences | Former 10% Holder | A - Grant | — | +1.89M | 1.89M | New | — |
| D | 2021-08-13 | 2021-08-11 | SRZN | Jarrett Jennifer | Former Dir | A - Grant | — | +30.0K | 30.0K | New | — |
| DMI | 2021-08-13 | 2021-08-11 | SRZN | Livingston Kevin Harold | Former CFO | A - Grant | — | +1.89M | 1.89M | New | — |
| DMI | 2021-08-13 | 2021-08-11 | SRZN | Livingston Kevin Harold | Former CFO | D - Sale to Iss | — | -1.89M | 0 | -100% | — |
| DI | 2021-08-13 | 2021-08-11 | SRZN | Livingston Kevin Harold | Former CFO | J - Other | — | -759.0K | 1.45M | -34% | — |
| D | 2021-08-13 | 2021-08-11 | SRZN | Santel Donald J | Former Dir | A - Grant | — | +30.0K | 30.0K | New | — |
| DMI | 2021-08-13 | 2021-08-11 | SRZN | Soffer Benny | FORMER Dir | A - Grant | — | +1.89M | 434.0K | New | — |
| DI | 2021-08-13 | 2021-08-11 | SRZN | Soffer Benny | FORMER Dir | J - Other | — | -759.0K | 1.45M | -34% | — |
| DMI | 2021-08-13 | 2021-08-11 | SRZN | Soffer Benny | FORMER Dir | D - Sale to Iss | — | -1.89M | 0 | -100% | — |
Purchase Sale Sale after option exercise All abbreviations